Multidisciplinary Management of Radiation-Induced Salivary Gland Carcinomas in the Modern Radiotherapy Era.

Abstract

Clinical data of ri-SGCs patients treated between 2015 and 2019 at a tertiary cancer center and a national hadron therapy facility were reviewed. Latent time (LT) from first RT to ri-SGCs diagnosis, overall (OS), and disease-free survival (DFS) were assessed. Thirteen patients developed 14 ri-SGCs (one patient had 2 synchronous ri-SCGs), after a median LT of 23 years (range 16-34). Parotid was the primary site in 8 cases (57%) and salivary duct carcinoma was the most frequent histotype (29%). Nine patients (69%) underwent surgery (Sx). Among them, 4 patients (31%) underwent Sx alone, 5 received post-operative treatments: 3 (23%) photon-based (X) reRT, one (8%) protons and carbon ions, one (8%) carbon ions only. One patient (8%) received definitive XRT. The remaining 3 patients (23%) received androgen deprivation therapy. With a median follow-up of 48 months (range 24-72), median OS and PFS were 74 and 24 months, respectively. In the subgroup of AR+ ri-SGCs, median PFS and OS were 12 and 74 months, respectively. Given the rarity of ri-SGCs, this work adds further knowledge to the paucity of literature. The management of these malignancies is extremely complex requiring a multidisciplinary treatment approach.

• Authors: Domenico Attilio Romanello, Zulfiyya Imamguliyeva, Stefano Cavalieri, Barbara Vischioni, Lorenza Gandola, Alberto Iannalfi, Nicola Alessandro Iacovelli, Lisa Licitra, Marco Guzzo, Cesare Piazza, Davide Lombardi, Barbara Diletto, Pasquale Quattrone, Giuseppina Calareso, Laura Deborah Locati, Ester Orlandi
• Journal: Cancers (Cancers (Basel)) Vol. 12 Issue 12 (Dec 14 2020) ISSN: 2072-6694 [Print] Switzerland
• PMID: 33327563 (Publication Type: Journal Article)